Jaguar Health, Inc. (NASDAQ:JAGX) | WebDisclosure

Basculer en Français

10646	Companies
226468	Keywords
154950	Articles
119878	Press releases

Home
Companies
Jaguar Health, Inc.

PRESS RELEASE

published on 05/23/2024 at 14:30, 2 years 1 month ago

Jaguar Health to Initiate Commercial Footprint in Cancer Supportive Care at American Society of Clinical Oncology (ASCO) Annual Meeting with Exhibit Booth for FDA-Approved Gelclair Oral Mucositis Product
Jaguar Health, Inc. announces commercial launch at ASCO Annual Meeting for Gelclair, FDA-approved oral mucositis product. Focus on cancer supportive care with phase 3 OnTarget trial results impending

Jaguar Health Phase 3 Trial Gelclair Oral Mucositis ASCO Annual Meeting
BRIEF

published on 05/17/2024 at 22:20, 2 years 1 month ago

Jaguar Health, Inc. Announces Reverse Stock Split

Jaguar Health Inc Reverse Stock Split Nasdaq Compliance Institutional Investors Stock Adjustment
BRIEF

published on 05/17/2024 at 22:20, 2 years 1 month ago

Jaguar Health, Inc. annonce un regroupement d'actions

Investisseurs Institutionnels Conformité NASDAQ Ajustement Des Stocks Regroupement Inversé Des Actions Jaguar Santé Inc.
PRESS RELEASE

published on 05/17/2024 at 22:15, 2 years 1 month ago

Jaguar Health, Inc. Announces Reverse Stock Split
Jaguar Health announces reverse split approval at Special Meeting of Stockholders to boost Nasdaq compliance. Stock trading on split-adjusted basis from May 23, 2024. Details in SEC filing

Stockholders Meeting Jaguar Health Nasdaq Compliance Reverse Split SEC Filing
BRIEF

published on 05/14/2024 at 14:05, 2 years 1 month ago

Jaguar Health Reports First Quarter 2024 Financial Results

Financial Results Crofelemer Jaguar Health Q1 2024 Gelclair
BRIEF

published on 05/14/2024 at 14:05, 2 years 1 month ago

Jaguar Health publie ses résultats financiers du premier trimestre 2024

Résultats Financiers Crofelemer Santé Jaguar T1 2024 Gelclair
PRESS RELEASE

published on 05/14/2024 at 14:00, 2 years 1 month ago

Jaguar Health Reports First Quarter 2024 Financial Results
Jaguar Health, Inc. reports Q1 2024 financial results, with revenue increasing 20% over Q1 2023. Key updates include OnTarget trial progress and Gelclair® commercial launch plans

Financial Results Jaguar Health Q1 2024 OnTarget Trial Gelclair
BRIEF

published on 05/13/2024 at 18:40, 2 years 1 month ago

Jaguar Health, Inc. Announces Q1 2024 Webcast to Discuss Financials and Corporate Updates

Earnings Report Jaguar Health Q1 2024 Financial Webcast Corporate Updates
BRIEF

published on 05/13/2024 at 18:40, 2 years 1 month ago

Jaguar Health, Inc. annonce une webdiffusion du premier trimestre 2024 pour discuter des données financières et des mises à jour de l'entreprise

Rapport Sur Les Revenus Santé Jaguar T1 2024 Webdiffusion Financière Mises À Jour De L'entreprise
PRESS RELEASE

published on 05/13/2024 at 18:35, 2 years 1 month ago

REMINDER: Jaguar Health to Hold Investor Webcast Tuesday, May 14th at 8:30 AM Eastern Regarding Q1 2024 Financials & Corporate Updates
Jaguar Health, Inc. to conduct investor webcast on May 14, 2024 at 8:30 a.m. Eastern to review first-quarter 2024 financials and provide corporate updates. Company plans to file its Earnings Report on the same day

Investor Webcast Form 10-Q Jaguar Health Inc. Corporate Updates First-quarter Financials

Accesswire

Published on 06/26/2026 at 15:05, 59 minutes ago

Vox Royalty Sells I-80 Gold Offtake Stream
Published on 06/26/2026 at 14:05, 1 hour 59 minutes ago

SouthGobi Announces Voting Results of Annual General Meeting of Shareholders
Published on 06/26/2026 at 14:00, 2 hours 4 minutes ago

Dateline Chairman Invests $1.95 million through Options Exercise
Published on 06/26/2026 at 13:00, 3 hours 4 minutes ago

Aclara Secures Tax Exemption Approval of Over US$20 Million For Its U.S. Heavy Rare Earth Separation Facility in Louisiana
Published on 06/26/2026 at 12:45, 3 hours 19 minutes ago

Northern Dynasty Reports Oral Arguments Held

View all ACCESSWIRE

EQS Group

Published on 06/26/2026 at 15:30, 33 minutes ago

JMGO Extends Special Savings Beyond Prime Day with N3 Ultimate at Its Best Price Since Launch
Published on 06/26/2026 at 15:23, 40 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Tate & Lyle plc
Published on 06/26/2026 at 15:23, 41 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare Group plc
Published on 06/26/2026 at 15:22, 41 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Senior plc
Published on 06/26/2026 at 15:21, 42 minutes ago

Form 8.3 - The Vanguard Group, Inc.: SEGRO plc

Les Echos

Published on 06/26/2026 at 14:44, 1 hour 19 minutes ago

Safran information
Published on 06/26/2026 at 14:44, 1 hour 19 minutes ago

Information Safran
Published on 06/26/2026 at 12:16, 3 hours 47 minutes ago

Rapport semestriel SIEHM au 30 avril 2026
Published on 06/26/2026 at 07:00, 9 hours 4 minutes ago

Advancing Women’s Health with Rapid Diagnostics: bioMérieux files a Dual 510(k) /CLIA Waiver application to the FDA for the BIOFIRE® SPOTFIRE® Vaginitis Panel
Published on 06/26/2026 at 07:00, 9 hours 4 minutes ago

Améliorer la santé des femmes grâce au diagnostic rapide : bioMérieux dépose auprès de la FDA une demande combinée d’autorisation 510(k) et de dérogation CLIA pour son test BIOFIRE® SPOTFIRE® Vaginitis Panel

View all LES ECHOS COMFI WIRE